drug · small molecule
iptacopan hydrochloride
Marketedupdated 6mo agoby $NVS NOVARTIS AG🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for paroxysmal nocturnal hemoglobinuria and iga glomerulonephritis and 2 investigational indications.
targets
Complement factor B
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 7, 2027
258 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Jul 15, 2041method-of-use (U-3895)US 11951101
- Jul 15, 2041method-of-use (U-4300)US 12453726
- May 25, 2041compositionUS 11603363
- May 17, 2041method-of-use (U-4161)US 12384758
- Aug 30, 2038method-of-use (U-3980)US 11723901
- Aug 30, 2038method-of-use (U-4181)US 12285422
- Jul 14, 2034method-of-use (U-3980)US 10093663
- Jul 14, 2034compositionUS 9682968
FDA exclusivities (4)
- Dec 5, 2030ODE-456Orphan Drug (7y)4.0y
- Dec 5, 2028NCENew Chemical Entity (5y)2.0y
- Mar 20, 2028I-963Indication (3y)1.3y
- Aug 7, 2027I-949Indication (3y)258d
News(10)
- Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict loomsAnalysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals.biospace · 4d ago
- Deaths, failed trials and other recent setbacks in the autoimmune spaceNovartis, Bristol Myers Squibb, argenx and more have recently been hit with challenges as they attempt to advance assets targeting autoimmune diseases, with some programs being axed entirely while…biospace · 5d ago
- Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked NovemberAlso lined up are target action dates for Sanofi’s Gaucher disease therapy, GSK’s lung cancer medicine and BridgeBio’s muscular dystrophy drug.biospace · 15d ago
- Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buyNovartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.biospace · 25d ago
- Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitionsRoche's Genentech has put numbers behind its phase 3 success in IgA nephropathy (IgAN), reporting that antisense oligonucleotide sefaxersen reduced a key marker of kidney damage by 43.1% compared w…fiercebiotech · 29d ago
- Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertainPfizer has called time on a phase 2 trial of its CXCR5 antibody in an autoimmune blood disorder, with the company tight-lipped on whether this marks the end of the road for the asset.fiercebiotech · 1mo ago
- Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issuesNovartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read o…biospace · 1mo ago
- Novartis scraps Fabhalta study in lupus nephritisNovartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” according to a federal clinical trials database. Fabhalta, also known as iptacopan, is a key…endpoints · 1mo ago
- Roche, Ionis RNA drug scores in kidney disease studyThe results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.biopharma_dive · 1mo ago
- Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease marketRoche has reported a phase 3 win for sefaxersen in kidney disease, teeing up talks with regulators about the path to approval for the Ionis-partnered, would-be blockbuster candidate.fiercebiotech · 1mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that